Toxicity of Cationic Lipid-DNA Complexes

被引:43
作者
Yew, Nelson S. [1 ]
Scheule, Ronald K. [1 ]
机构
[1] Genzyme Corp, Framingham, MA 01701 USA
来源
NON-VIRAL VECTORS FOR GENE THERAPY, 2ND EDITION: PART 1 | 2005年 / 53卷
关键词
D O I
10.1016/S0065-2660(05)53007-4
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
As with any conventional drug, the body's response to cationic lipid-DNA complexes is highly dependent on both the dose administered and the route of delivery. At relatively low doses there is little to no effect on organ function or tissue architecture, but at higher doses, acute inflammation and tissue damage can occur that is sometimes quite profound. Of the two most common routes of delivery, intravenous (IV) or intrapulmonary, IV administration tends to cause more severe adverse effects and can be lethal at higher doses of complex. Both routes activate an innate immune response that includes the induction of proinflammatory cytokines and immune cell activation, a major portion of which has been attributed to the presence of immunostimulatory CpG motifs within the plasmid DNA vector. Removing CpGs from the plasmid vector reduces several, but not all of the acute inflammatory responses to cationic lipid-DNA complexes. Therefore, other strategies are required to improve the therapeutic potential of these vectors, such as transient immune suppression, aerosolization of the complex, and novel formulations that have increased efficiency of transduction and decreased interaction with immune cells. (C) 2005, Elsevier Inc.
引用
收藏
页码:189 / 214
页数:26
相关论文
共 89 条
[1]   Toll-like receptors: critical proteins linking innate and acquired immunity [J].
Akira, S ;
Takeda, K ;
Kaisho, T .
NATURE IMMUNOLOGY, 2001, 2 (08) :675-680
[2]   Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis:: a double-blind placebo-controlled trial [J].
Alton, EWFW ;
Stern, M ;
Farley, R ;
Jaffe, A ;
Chadwick, SL ;
Phillips, J ;
Davies, J ;
Smith, SN ;
Browning, J ;
Davies, MG ;
Hodson, ME ;
Durham, SR ;
Li, D ;
Jeffery, PK ;
Scallan, M ;
Balfour, R ;
Eastman, SJ ;
Cheng, SH ;
Smith, AE ;
Meeker, D ;
Geddes, DM .
LANCET, 1999, 353 (9157) :947-954
[3]   In vivo characteristics of cationic liposomes as delivery vectors for gene therapy [J].
Audouy, SAL ;
de Leij, LFMH ;
Hoekstra, D ;
Molema, G .
PHARMACEUTICAL RESEARCH, 2002, 19 (11) :1599-1605
[4]   Effects of complement depletion on the pharmacokinetics and gene delivery mediated by cationic lipid DNA complexes [J].
Barron, LG ;
Meyer, KB ;
Szoka, FC .
HUMAN GENE THERAPY, 1998, 9 (03) :315-323
[5]   Safety of a single aerosol administration of escalating doses of the cationic lipid GL-67/DOPE/DMPE-PEG(5000) formulation to the lungs of normal volunteers [J].
Chadwick, SL ;
Kingston, HD ;
Stern, M ;
Cook, RM ;
OConnor, BJ ;
Lukasson, M ;
Balfour, RP ;
Rosenberg, M ;
Cheng, SH ;
Smith, AE ;
Meeker, DP ;
Geedes, DM ;
Alton, EWFW .
GENE THERAPY, 1997, 4 (09) :937-942
[6]   Identification of methylated CpG motifs as inhibitors of the immune stimulatory CpG motifs [J].
Chen, Y ;
Lenert, P ;
Weeratna, R ;
McCluskie, M ;
Wu, T ;
Davis, HL ;
Krieg, AM .
GENE THERAPY, 2001, 8 (13) :1024-1032
[7]   Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo [J].
Chen, ZY ;
He, CY ;
Ehrhardt, A ;
Kay, MA .
MOLECULAR THERAPY, 2003, 8 (03) :495-500
[8]   Autoreactive T cells persist in rats protected against experimental autoimmune encephalomyelitis and can be activated through stimulation of innate immunity [J].
Conant, SB ;
Swanborg, RH .
JOURNAL OF IMMUNOLOGY, 2004, 172 (09) :5322-5328
[9]  
Cowdery J, 1996, J IMMUNOL, V156, P4570
[10]   Minicircle:: an improved DNA molecule for in vitro and in vivo gene transfer [J].
Darquet, AM ;
Rangara, R ;
Kreiss, P ;
Schwartz, B ;
Naimi, S ;
Delaère, P ;
Crouzet, J ;
Scherman, D .
GENE THERAPY, 1999, 6 (02) :209-218